SUTENT® (sunitinib malate) Capsules Indication Statement
SUTENT is indicated for the treatment of advanced renal cell carcinoma (RCC), for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate, and for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with unresectable locally advanced or metastatic disease.
Managing Side Effects
Need help managing your patients' side effects? Patients may experience a variety of side effects on SUTENT – learn about ways to help patients cope.
Treatment Information
Need information about SUTENT treatment? Find patient case studies, dosing guides, plans of care, and educational videos by a renowned oncology nurse.
Printable Resources
Need printable tools and information?
Patients often have questions about treatment, including ones about finances and insurance. Help address their concerns with these resources.
If your patients have questions about their treatment, encourage them to call
1-877-578-8368
for a personalized consultation.
The SUTENT Patient Call Center is available 8 AM to 11 PM ET.
Manufactured by Wyeth Pharmaceuticals Inc. Marketed by Pfizer Inc. 
